MACAU DAILY TIMES 澳門每日時報

Top Menu

  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia

Main Menu

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
logo
FOUNDER & PUBLISHER Kowie Geldenhuys
EDITOR-IN-CHIEF Paulo Coutinho
Macau,

MACAU DAILY TIMES 澳門每日時報

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • 1 in 14 residents has diabetes, SSM survey finds

  • Grand Prix opens with citywide cultural festival

  • Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

  • 39 land parcels earmarked for temporary public facilities

  • Grand Prix road closures to disrupt 51 bus routes

  • Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

World
Home›World›Study hints antibody drug may cut Covid-19 hospitalizations

Study hints antibody drug may cut Covid-19 hospitalizations

By -
Thursday, September 17, 2020
96
0

A drug company says that partial results from a study testing an antibody drug give hints that it may help mild to moderately ill COVID-19 patients from needing to be hospitalized, a goal no current coronavirus medicine has been able to meet.
Eli Lilly announced the results yesterday in a press release, but they have not been published or reviewed by independent scientists.
The drug missed the study’s main goal of reducing the amount of virus patients had after 11 days, except at the middle of three doses being tested. However, most study participants, even those given a placebo treatment, had cleared the virus by then, so that time point now seems too late to judge that potential benefit, the company said.
Other tests suggest the drug was reducing virus sooner, and the results are an encouraging “proof of principle” as this and other studies continue, Lilly said.
The company said it would talk with regulators about possible next steps but that it was too soon to speculate on whether these interim results might lead to any action to allow early use.
“I’m strongly encouraged” by the results, said Dr. Myron Cohen, a University of North Carolina virologist. He had no role in the Lilly study but helps direct antibody studies for a public-private research group the federal government formed to speed testing of these drugs.
“This seems to demonstrate what we thought” — that such drugs would give a benefit, he said.
Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. The blood of survivors is being tested as a treatment for COVID-19 patients because it contains such antibodies, but the strength and types of antibodies varies depending on each donor, and doing this on a large scale is impractical.
The drugs that Lilly and other companies are testing are concentrated versions of specific antibodies that worked best against the coronavirus in lab and animal tests, and can be made in large, standardized doses.
They are being tested to treat newly diagnosed COVID-19 patients in hope of preventing serious disease or death, and to try to prevent infection in people at high risk of that such as nursing home residents and health workers.
The results come from 450 people in a mid-stage study testing an antibody jointly developed by Indianapolis-based Lilly and the Canadian company AbCellera in people with COVID-19 symptoms not severe enough to warrant hospitalization. The drug is given once through an IV and was tested at three doses. Neither the patients nor their doctors knew which patients received the drug or placebo infusions.
Hospitalization or ER visits occurred in 1.7%, or 5 of 302 patients given the drug and 6% or 9 of 150 of those given placebo. The company did not disclose whether those results met scientific tests to rule out that they could have occurred by chance alone.
The company felt that giving the actual numbers “told the story in the most balanced way,” said Lilly’s chief scientific officer, Dr. Daniel Skovronsky. MARILYNN MARCHIONE, AP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

Like this:

Like Loading…

Related

Previous Article

World Views | Retailers think you can’t ...

Next Article

The Buzz | Report finds global economic ...

Related articles More from author

  • World

    The Buzz: Van slips off mountain road in Nepal, killing 8

    Monday, October 27, 2014
    By -
  • World

    This Day in History | 1954 – New York’s Ellis Island closes

    Thursday, November 12, 2015
    By -
  • World

    Diplomacy | Blinken, Lapid meet in Rome amid reset US-Israel relations

    Monday, June 28, 2021
    By -
  • World

    Syria | Aid groups criticize UN Security Council over humanitarian crisis

    Friday, March 13, 2015
    By -
  • World

    White House warns Russia may use chemical weapons in Ukraine

    Friday, March 11, 2022
    By -
  • World

    Shelling resumes near Ukraine nuclear plant, despite risks

    Thursday, September 8, 2022
    By -

Leave a reply Cancel reply

You must be logged in to post a comment.

  • HeadlinesMacau

    Policy Adress | Administration and Justice: Lawmakers criticize top officials’ accountability system

  • Macau

    Museum of Art launches exhibition of Chen Zhifo

  • World

    Carol Burnett returning to ‘Mad About You’ revival

DAILY EDITION

Monday, November 16, 2026 – edition no. 5075
Monday, November 16, 2026 – edition no. 5075

Greater Bay

MDT MACAU GRAND PRIX SPECIAL

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Timeline

  • Monday, November 16, 2026

    1 in 14 residents has diabetes, SSM survey finds

  • Monday, November 16, 2026

    Grand Prix opens with citywide cultural festival

  • Monday, November 16, 2026

    Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

  • Monday, November 16, 2026

    39 land parcels earmarked for temporary public facilities

  • Monday, November 16, 2026

    Grand Prix road closures to disrupt 51 bus routes

  • Monday, November 16, 2026

    Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

  • Monday, November 16, 2026

    Creative industries need creative people

  • Monday, November 16, 2026

    Strictly upholding the bottom line of the rule of law and safeguarding its core values

  • Monday, November 16, 2026

    Strictly adhering to statutory procedures; Safeguarding national security interests

  • Monday, November 16, 2026

    21 more school and nursery entrances designated smoke-free

Extra Times

Extra TimesHeadlinesTaste of Edesia

Three chefs. One horizon. Six Michelin stars

There are moments when separate culinary philosophies align so precisely that the result transcends mere menu-making. At Chef Tam’s Seasons, Wynn Palace, three two-Michelin-starred titans—each ranked among Asia’s 50 Best ...
  • James Gray delivers a milestone crime drama in ‘Paper Tiger’

    By MDT/AP
    Friday, November 13, 2026
  • The Twelve25 × La Vie exchange

    By -
    Friday, November 13, 2026
  • A fiery milestone: Feng Wei Ju’s 20th anniversary tribute to Starworld Macau

    By Irene Sam, MDT
    Friday, November 6, 2026
  • In ‘I Play Rocky,’ a middleweight crowd-pleaser about the making of a classic

    By MDT/AP
    Friday, November 6, 2026
  • Recent

  • Popular

  • 1 in 14 residents has diabetes, SSM survey finds

    By Nadia Shaw, MDT
    Monday, November 16, 2026
  • Grand Prix opens with citywide cultural festival

    By Renato Marques, MDT
    Monday, November 16, 2026
  • Gov’t launches cross-border elderly care pilot with 50 places in Zhuhai

    By Yuki Lei, MDT
    Monday, November 16, 2026
  • 39 land parcels earmarked for temporary public facilities

    By Yuki Lei, MDT
    Monday, November 16, 2026
  • Grand Prix road closures to disrupt 51 bus routes

    By Nadia Shaw, MDT
    Monday, November 16, 2026
  • Southeast Asian leaders open annual summit with major conflicts and their impact topping the agenda 

    By -
    Monday, November 16, 2026
  • Creative industries need creative people

    By Renato Marques, MDT
    Monday, November 16, 2026
  • Canidrome may have its days numbered, decision in ‘one or two months’

    By Paulo Coutinho, MDT
    Thursday, May 26, 2016
  • Animal Welfare | Macau: Anima slams Canidrome management for avoiding debate

    By -
    Wednesday, May 4, 2016
  • Editorial | Canidoomed

    By Paulo Coutinho, MDT
    Wednesday, June 1, 2016
  • Animal Welfare | Canidrome presented with ultimatum: close or move

    By Daniel Beitler, MDT
    Friday, July 22, 2016
  • Australia regulator cracks down on alleged exportation of dogs to Macau

    By Paulo Coutinho, MDT
    Friday, June 10, 2016
  • Animal rights | Canidrome: Anima in fresh airline negotiations as Canidrome closure looks more likely

    By Daniel Beitler, MDT
    Friday, May 27, 2016
  • USE OF ENGLISH IN MACAU | A ‘de facto’ official language

    By Catarina Pinto
    Monday, July 6, 2015
  • Contact our Administrator
  • Contact our Editor-in-Chief
  • Contacts
  • Our Team
  • Privacy Policy
  • Terms and Conditions
  • Editorial Statute
  • Code of Ethics
COPYRIGHT © MACAU DAILY TIMES 2008-2026. ALL RIGHTS RESERVED
MACAU DAILY TIMES
  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
Loading Comments...

You must be logged in to post a comment.

%d